7/24/2014 9:47:28 AM
Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy
vaccines, today provides a trading update for the year to 30 June 2014 ahead of its preliminary results
to be announced on 22 September 2014.
The Company reports that it expects revenues, before milestones and rebates, of approximately
£45.7m (2013: £39.9m), an increase of 14% on the previous year and marginally ahead of market
expectations. This double digit sales growth has been driven by the Company's improving trading
performance as it continues to increase its market share in all of its main markets and supported by a
foreign exchange benefit of £2.3m.
Manuel Llobet, Chief Executive Officer, commented as follows:-
“Along with resuming our plans for Pollinex Quattro in the US, strengthening our position in Europe
has been a top management priority. Our focus on ultra-short, aluminium free, subcutaneous allergy
vaccines is driving consistent growth across all our key European markets. The strong financial
performance demonstrates that we are building a sound, attractive business in Europe that will be the
platform for our expansion globally."
For further information
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
Peel Hunt LLP
+44 (0) 20 7418 8900
James Steel / Clare Terlouw
+44 (0) 20 3727 1000
Simon Conway / Victoria Foster Mitchell / Mo Noonan
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a
growing business achieving revenues in the prior financial year of £39.3 million mainly in Europe
through its own sales and marketing infrastructure and further afield through distributors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by